# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 101-110 of 2216 results.
Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma
Status: Active, not recruiting
Last Changed: Mar 11, 2020
First Received: Nov 01, 2016
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Decitabine
Locations: Shanghai Ruijin Hospital, Shanghai, China
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Mar 13, 2020
First Received: Apr 07, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Biological samples collection
Locations: CHU Caen, Caen, France
Hopital Henri Mondor, Creteil, France
CHU Le Bocage, Dijon, France
CH Départemental, La Roche sur Yon, France
CHU Claude Hurriez, Lille, France
... and 11 other locations.
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
Status: Active, not recruiting
Last Changed: Jul 21, 2020
First Received: Sep 28, 2018
Disease(s): Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): INCB053914, INCB050465
Locations: University of Arizona Cancer Center, Tucson, Arizona, United States
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
Clinical Research Alliance, Lake Success, New York, United States
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2)
Status: Recruiting
Last Changed: Jun 04, 2020
First Received: Jun 04, 2020
Disease(s): Relapsed/Refractory Large B Cell Lymphoma
Intervention(s): ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Locations: Colorado Blood Cancer Institute, Denver, Colorado, United States
Moffitt Cancer Center, Tampa, Florida, United States
SCRI, Austin, Texas, United States
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Mar 16, 2020
First Received: May 05, 2016
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Rituximab (RTX), Tafasitamab, Bendamustine (BEN)
Locations: MorphoSys Research Site, Anaheim, California, United States
MorphoSys Research Site, Bakersfield, California, United States
Morphosys Research Site, Burbank, California, United States
Morphosys Research Site, Fresno, California, United States
MorphoSys Research Site, Los Angeles, California, United States
... and 154 other locations.
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: Mar 13, 2019
First Received: Mar 13, 2019
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Pembrolizumab and CXD101
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Status: Active, not recruiting
Last Changed: Sep 25, 2020
First Received: Jan 30, 2017
Disease(s): Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Intervention(s): Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Weill Cornell Medicine, New York, New York, United States
Ohio State University Medical Center, Columbus, Ohio, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
... and 2 other locations.
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Status: Terminated
Last Changed: Sep 25, 2019
First Received: Feb 03, 2011
Disease(s): Low Grade B Cell Lymphoma
Intervention(s): VTX-2337 plus radiotherapy
Locations: Stanford Cancer Center, Stanford, California, United States
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Sep 10, 2020
First Received: Jan 16, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Ibrutinib Oral Capsule [Imbruvica], R-CHOEP chemotherapy
Locations: HELIOS Hospital Berlin-Buch, Berlin, Germany
Hospital Chemnitz, Chemnitz, Germany
University Hospital Cologne, Cologne, Germany
University Hospital Göttingen, Göttingen, Germany
University Hospital Hamburg-Eppendorf, Hamburg, Germany
... and 7 other locations.
A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
Status: Completed
Last Changed: Mar 04, 2008
First Received: Dec 10, 2002
Disease(s): B Cell Lymphoma
Intervention(s): IgG-RFB4-SMPT-dgA
Locations: National Cancer Institute (NCI), Bethesda, Maryland, United States